Avalo Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotechnology company specializing in immune dysregulation treatments, has announced its participation in two major investor conferences in March 2025.
The company will deliver a corporate presentation at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 3:10 pm ET. Additionally, Avalo will participate in 1x1 and small group meetings at the Leerink Partners Global Healthcare Conference in Miami on March 12, 2025.
Interested parties can access live webcasts and replays of the presentations through the 'News / Events' section of Avalo's investor relations website at ir.avalotx.com. The archived webcasts will remain available for a minimum of 30 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction – AVTX
In the trading session that priced this news, AVTX declined 4.03%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March.
TD Cowen 45th Annual Health Care Conference, Boston
Corporate Presentation
March 3, 2025, at 3:10 pm ET
Leerink Partners Global Healthcare Conference, Miami
1x1 and small group meetings
March 12, 2025
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
